4503 — Astellas Pharma Share News
0.000.00%
Last trade - 00:00Brief: Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer
Vir Biotech drops after $150 mln stock sale
Vir Biotech soars again after prostate cancer drug collaboration with Astellas
Vir Biotech slips after unveiling $200 mln stock offering plans
Vir Biotechnology soars on Q4 results beat, Astellas collaboration
Brief: Astellas & Vir Biotechnology Collaborate To Advance VIR-5500
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Brief: Evinova Announces Strategic Collaborations With Astellas, Astrazeneca & Bristol Myers Squibb
India's Zydus agrees $120 million settlement with Astellas over bladder drug (updated)
India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment
Brief: Zydus Lifesciences Enters Settlement Agreement With Astellas Over Myrbetriq
Citi says Lupin-Astellas settlement may delay rival generic launches
India's Lupin settles US patent dispute with Astellas Pharma for $90 million (updated)
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Brief: Lupin Enters Settlement And License Agreement With Astellas
Table: Astellas -9-MTH group results (IFRS)
Brief: Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Merck up after FDA approves combination treatment for muscle invasive bladder cancer
Table: Astellas 6-MTH group results (IFRS)